PT  - JOURNAL ARTICLE
AU  - Atchley, Travis J.
AU  - Estevez-Ordonez, Dagoberto
AU  - Laskay, Nicholas M.B.
AU  - Tabibian, Borna E.
AU  - Harrigan, Mark R.
TI  - Endovascular thrombectomy for the treatment of large ischemic stroke: a systematic review and meta-analysis of randomized control trials
AID  - 10.1101/2023.02.27.23286534
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.02.27.23286534
4099  - http://medrxiv.org/content/early/2023/03/01/2023.02.27.23286534.short
4100  - http://medrxiv.org/content/early/2023/03/01/2023.02.27.23286534.full
AB  - Importance Endovascular thrombectomy (ET) has previously been reserved for patients with small to medium acute ischemic strokes. Three recent randomized control trials (RCTs) have demonstrated functional benefit and risk profiles for ET in large volume ischemic strokes.Objective The primary objective of the meta-analysis was to determine the combined benefit of ET in adult patients with large volume acute ischemic strokes and to better determine the risk of adverse events following ET.Data Sources We systematically searched MEDLINE, EMBASE, SCOPUS, the Cochrane Central Register of Controlled, and Google Scholar for all RCTs published in English language between January 1, 2010, to February 19, 2023.Study Selection We included only RCTs specifically comparing ET to medical therapy in patients with acute ischemic stroke with large volume infarctions as defined by Alberta Stroke Program Early Computed Tomography Score (ASPECTS) 3-5 or calculated infarct volume of > 50-70mL. Two independent reviewers screened potential studies for full text review and metaanalysis inclusion with conflicts being resolved by consensus or third reviewer.Data Extraction and Synthesis Data was extracted based on pre-specified variables on study methods and design, participant characteristics, analysis approach, as well as efficacy and safety outcomes. Results were combined using a restricted maximum-likelihood estimation random-effects model. Studies were assessed for potential bias and quality of evidence.Main Outcome(s) and Measure(s) The prespecified primary outcome was an overall ordinal shift across the range of modified Rankin scale scores toward a better outcome at 90 days following either ET or medical management for patients with large volume ischemic strokes.Results A total of 3044 studies were screened, and 29 underwent full text review. 3 RCTs (1011 patients) were included in the analysis. The pooled random effects model for the primary outcome of mRS improvement favored ET over medical management, generalized odds ratio 1.55 [95% CI 1.25 – 1.91, T2 = 0.01, I2 = 42.84%]. There was a trend toward increased risk of symptomatic ICH in the ET group, relative risk 1.85 [95% CI 0.94 – 3.63, T2 = 0.00, I2 = 0.00%].Conclusions and Relevance In patients with large volume ischemic strokes, ET has a clear functional benefit and does not confer increased risk of significant complications compared to medical management alone.Competing Interest StatementThe authors have declared no competing interest.Clinical Protocols https://inplasy.com/inplasy-2023-2-0107/ Funding StatementResearch reported in this publication was supported in part by the National Institute of Neurological Disorders and Stroke of the National Institutes of Health under award number R25NS079188 (DEO). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. This study was also completed while DEO was a Cornwall Clinical Scholar supported by UAB.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData and syntax used for the analysis have been made publicly available through GitHub https://github.com/estevezdo/Thrombectomy-in-Large-Volume-Strokes-SysRev-Metan